PTH1R and osteoporosis: Several studies summarized by Cosman and colleagues(23) describe BMD responses in individuals with osteoporosis who transitioned from bisphosphonate therapy to PTHR1 agonists, a treatment sequence paradigm that is increasingly recognized as being suboptimal for maximizing BMD gains.